Volume 23, Issue 1, Pages (January 2013)

Slides:



Advertisements
Similar presentations
Personalized Lung Cancer Treatment: Targeting Stem Cell Pathways David M. Jablons, M.D. Professor and Chief Thoracic Surgery Ada Distinguished Professor.
Advertisements

Volume 30, Issue 3, Pages (September 2016)
Volume 16, Issue 2, Pages (August 2009)
“Atypical” Regulation of Hedgehog-Dependent Cancers
DNMT3B Overexpression by Deregulation of FOXO3a-Mediated Transcription Repression and MDM2 Overexpression in Lung Cancer  Yi-Chieh Yang, MS, Yen-An Tang,
Volume 26, Issue 2, Pages (August 2014)
Developmental biology informs cancer
Volume 20, Issue 4, Pages e4 (April 2017)
Volume 19, Issue 7, Pages (July 2017)
Volume 5, Issue 2, Pages (August 2009)
Accelerating drug discovery: Open source cancer cell biology?
The Role of Patch in Basal Cell Carcinoma
Volume 17, Issue 4, Pages (April 2010)
The Hedgehog Signalling Pathway in the Gastrointestinal Tract: Implications for Development, Homeostasis, and Disease  Charlie Lees, Sarah Howie, R. Balfour.
A Mitochondrial Power Play in Lymphoma
Volume 14, Issue 3, Pages (September 2008)
Volume 28, Issue 3, Pages (September 2015)
Volume 26, Issue 1, Pages 1-2 (July 2014)
Volume 73, Issue 1, Pages 4-8 (January 2018)
Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro  Min You, PhD, Javier Varona-Santos,
Volume 28, Issue 4, Pages (October 2015)
Volume 26, Issue 4, Pages (October 2014)
Volume 40, Issue 4, Pages (November 2010)
Volume 18, Issue 4, Pages (April 2011)
Coordinate Transcriptional Regulation by ERG and Androgen Receptor in Fusion- Positive Prostate Cancers  Yu Chen, Charles L. Sawyers  Cancer Cell  Volume.
Volume 18, Issue 1, Pages (July 2010)
Volume 28, Issue 1, Pages (July 2015)
Volume 19, Issue 3, Pages (March 2017)
Volume 23, Issue 6, Pages (June 2013)
Thomas M. Carroll, Jonathan S
Volume 19, Issue 10, Pages (June 2017)
Vismodegib Resistance in Basal Cell Carcinoma: Not a Smooth Fit
Personalized Medicine: Patient-Predictive Panel Power
Volume 27, Issue 3, Pages (March 2015)
Volume 27, Issue 1, Pages (January 2015)
Volume 11, Issue 1, Pages (April 2015)
Volume 18, Issue 1, Pages (July 2010)
Small Interfering RNA Journal of Investigative Dermatology
Volume 15, Issue 5, Pages (May 2009)
Lack of Evidence for Activation of the Hedgehog Pathway in Psoriasis
Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S Improved tumor response.
miR-124 Inhibits Lung Tumorigenesis Induced by K-ras Mutation and NNK
Volume 5, Issue 3, Pages (November 2013)
A, left: indicated MEFs were transfected as described in the Methods section. A, left: indicated MEFs were transfected as described in the Methods section.
Volume 30, Issue 3, Pages (September 2016)
Volume 13, Issue 5, Pages (November 2015)
Rolling the Genetic Dice: Neutral and Deleterious Smoothened Mutations in Drug- Resistant Basal Cell Carcinoma  Scott X. Atwood, Kavita Y. Sarin, Jiang.
Volume 21, Issue 12, Pages (December 2014)
Volume 19, Issue 8, Pages (August 2012)
Volume 6, Issue 3, Pages (September 2004)
Ekaterina Pak, Rosalind A. Segal  Developmental Cell 
William G. Nelson, Michael C. Haffner, Srinivasan Yegnasubramanian 
Volume 14, Issue 4, Pages (October 2008)
Volume 14, Issue 5, Pages (May 2008)
Volume 8, Issue 4, Pages (October 2005)
Negative Regulation of Tumor Suppressor p53 by MicroRNA miR-504
Smoothing Out Drug Resistance
Volume 10, Issue 5, Pages (May 2006)
MiR-409 Inhibits Human Non-Small-Cell Lung Cancer Progression by Directly Targeting SPIN1  Qi Song, Quanbo Ji, Jingbo Xiao, Fang Li, Lingxiong Wang, Yin.
Drugging MYCN through an Allosteric Transition in Aurora Kinase A
Hedgehog signaling plays a conserved role in inhibiting fat formation
Padmanee Sharma, James P. Allison  Cell 
Volume 33, Issue 1, Pages (April 2015)
The Expression of MicroRNA-598 Inhibits Ovarian Cancer Cell Proliferation and Metastasis by Targeting URI  Feng Xing, Shuo Wang, Jianhong Zhou  Molecular.
Volume 14, Issue 3, Pages (September 2008)
GR cells are dependent upon sustained CDC25C signaling as pharmacologic or genetic inhibition of CDC25C induce synthetic lethality. GR cells are dependent.
A Direct HDAC4-MAP Kinase Crosstalk Activates Muscle Atrophy Program
Schematic demonstration of hedgehog signal pathway.
Ibrutinib Treatment of CLL: The Cancer Fights Back
Presentation transcript:

Volume 23, Issue 1, Pages 23-34 (January 2013) Itraconazole and Arsenic Trioxide Inhibit Hedgehog Pathway Activation and Tumor Growth Associated with Acquired Resistance to Smoothened Antagonists  James Kim, Blake T. Aftab, Jean Y. Tang, Daniel Kim, Alex H. Lee, Melika Rezaee, Jynho Kim, Baozhi Chen, Emily M. King, Alexandra Borodovsky, Gregory J. Riggins, Ervin H. Epstein, Philip A. Beachy, Charles M. Rudin  Cancer Cell  Volume 23, Issue 1, Pages 23-34 (January 2013) DOI: 10.1016/j.ccr.2012.11.017 Copyright © 2013 Elsevier Inc. Terms and Conditions

Cancer Cell 2013 23, 23-34DOI: (10.1016/j.ccr.2012.11.017) Copyright © 2013 Elsevier Inc. Terms and Conditions

Figure 1 A Simplified View of Hh Signaling Binding of a Hh ligand to Patched (PTCH) derepresses SMO, causing activation and translocation to the nucleus of GLI2, which initiates the transcription of target genes, including PTCH and GLI1. Cyclopamine, its derivative, IPI-926, and its mimics, GDC-0449 and NVP-LDE225, all bind competitively to a site within the transmembrane portion of SMO; the SMO missense mutations indicated by yellow asterisks decrease binding and confer resistance to these drugs. Itraconazole inhibits SMO by a distinct mechanism, and ATO inhibits the pathway at the level of GLI. Cancer Cell 2013 23, 23-34DOI: (10.1016/j.ccr.2012.11.017) Copyright © 2013 Elsevier Inc. Terms and Conditions

Figure 2 Itraconazole Inhibits the Hh Pathway in the Context of GDC-0449 Resistant SMOD477G (A and B) Relative Hh pathway activity as determined by expression of 8×-GLI-luciferase reporter in SHH-N stimulated Smo−/− MEFs expressing SMOWT (blue) or SMOD477G (red) treated with (A) GDC-0449 or (B) itraconazole. Data represent mean of triplicates ± SD. (C and D) Proliferation of Ptch+/−; p53−/− MB tumorspheres expressing endogenous SMOWT (blue) or SMOD477G (red) treated with increasing doses of (C) GDC-0449 and (D) itraconazole. Data represent mean of quadruplicates ± SEM. (E and F) Relative Gli1 mRNA transcription in (C) GDC-0449-treated and (D) itraconazole-treated MB tumorspheres expressing endogenous SMOWT (blue) or SMOD477G (red). Data represent mean of quadruplicates ± SEM. See also Figure S1. Cancer Cell 2013 23, 23-34DOI: (10.1016/j.ccr.2012.11.017) Copyright © 2013 Elsevier Inc. Terms and Conditions

Figure 3 Itraconazole Combines with Cyclopamine to Inhibit GDC-0449-Resistant SMO Function (A) Relative 8×-GLI-luciferase expression in SHH-N-stimulated Smo−/− MEFs expressing SMOWT or SMOD477G, treated with GDC-0449, itraconazole, or both. (B) Effect of KAAD-cyclopamine 100 nM, itraconazole 2 μM, or both on SHH-N-stimulated 8×-GLI-luciferase expression in Smo−/− MEFs expressing SMOD477G. (C) Dose-response curves of KAAD-cyclopamine for SHH-N activated signaling in Smo−/− MEFs expressing SMOD477G, in the presence or absence of itraconazole. All data represent mean of triplicates ± SD. See also Figure S2 and Table S1. Cancer Cell 2013 23, 23-34DOI: (10.1016/j.ccr.2012.11.017) Copyright © 2013 Elsevier Inc. Terms and Conditions

Figure 4 ATO and Itraconazole Combine to Inhibit Hh Pathway Activation and Tumor Growth by SMOWT (A and B) Effect of combination therapy on the IC50 concentrations of itraconazole (A) or ATO (B) in NIH 3T3 cells expressing endogenous SMOWT stimulated with SHH-N in 8×-GLI-luciferase signaling assays. Data represent mean of triplicates ± SD. (C and D) Nude mice with SMOWT hindflank MB allografts were treated with vehicle control (40% cyclodextrin orally twice daily, n = 7 tumors; black), GDC-0449 (100 mg/kg orally twice daily, n = 7; red), ATO (7.5 mg/kg i.p. once daily, n = 7 tumors; green), itraconazole (75 mg/kg orally twice daily, n = 7 tumors; blue), or both ATO and itraconazole (n = 7 tumors; blue-green). Effect of GDC-0449, ATO, itraconazole, or the combination of ATO and itraconazole on (C) tumor growth and (D) Gli1 mRNA expression compared to vehicle control. Data represent group means ± SEM (∗p < 0.01 versus vehicle; ∗∗p < 0.01 versus ATO alone; ∗∗∗p < 0.01 versus itraconazole alone). See also Figure S3 and Tables S2 and S3. Cancer Cell 2013 23, 23-34DOI: (10.1016/j.ccr.2012.11.017) Copyright © 2013 Elsevier Inc. Terms and Conditions

Figure 5 Combination of ATO and Itraconazole Inhibits Tumor Growth of Hh-Dependent BCC NOD/SCID mice with established K14-CreER/+;Ptch+/−;p53fl/fl BCC allografts were treated with vehicle control (40% cyclodextrin orally twice daily, n = 4 tumors; black), ATO (7.5mg/kg i.p. once daily, n = 6 tumors; green), itraconazole (75 mg/kg orally twice daily, n = 10 tumors; blue), or both ATO and itraconazole (n = 16 tumors; blue-green; p < 0.01 for the combination compared to either itraconazole or ATO alone). Data represent group means ± SEM. Cancer Cell 2013 23, 23-34DOI: (10.1016/j.ccr.2012.11.017) Copyright © 2013 Elsevier Inc. Terms and Conditions

Figure 6 ATO and Itraconazole Combine to Inhibit SMOD477G Activity and Tumor Growth, and Improve Survival in an Orthotopic Medulloblastoma Model (A–C) Smo−/− MEFs were transfected with either SmoWT or SmoD477G and stimulated with SHH-N. Data represent mean of triplicates ± SD. (A) Relative Hh pathway activity as assessed by relative 8 × -GLI-luciferase expression in the presence or absence of itraconazole, ATO, or the combination. Dashed line represents the level of pathway inhibition of SMOWT by itraconazole 1.5 μM. (B) Effect of the addition of increasing doses of ATO to itraconazole in cells expressing SMOD477G. (C) Effect of increasing doses of itraconazole on the IC50 of ATO in cells expressing SMOD477G. (D and E) Nude mice with established SMOD477G MB allografts were treated with vehicle control (40% cyclodextrin orally twice daily, n = 8 tumors; black), GDC-0449 (100 mg/kg orally twice daily, n = 8; red); ATO (7.5mg/kg i.p. once daily, n = 8 tumors; green), itraconazole (75 mg/kg orally twice daily, n = 8 tumors; blue), or both ATO and oral itraconazole (n = 8 tumors; blue-green); (D) tumor growth over time and (E) relative Gli1 mRNA expression. Data represent group means ± SEM (∗p < 0.01 versus vehicle; ∗∗p < 0.01 versus ATO alone; ∗∗∗p < 0.01 versus ITRA alone). (F) Kaplan-Meier survival analysis of an orthotopic model of SMOD477G MB treated with vehicle control (n = 9), GDC-0449 (n = 9), itraconazole (n = 9), ATO (n = 9), or both ATO and itraconazole (n = 9) using the same doses as in (D). See also Figure S4 and Table S4. Cancer Cell 2013 23, 23-34DOI: (10.1016/j.ccr.2012.11.017) Copyright © 2013 Elsevier Inc. Terms and Conditions

Figure 7 Combination of ATO and Itraconazole Inhibits All Other Known Drug-Resistant SMO Mutants and GLI2 Overexpression (A–G) SHH-N stimulated Smo−/− MEFs were transfected with (A) SmoWT or mutant Smo constructs resistant to (B) GDC-0449 or (C–G) NVP-LDE225. The effects of itraconazole, ATO, and the combination of both agents on Hh pathway activity was assessed by relative 8×-GLI-luciferase activity. Labels in (B–G) indicate the mutant SMO that was expressed. (H) Effect of itraconazole, ATO, or the combination on relative 8×-GLI-luciferase activity in NIH 3T3 cells transfected with Gli2 ± SHH-N stimulation. Data represent mean of triplicates ± SD. See also Figure S5. Cancer Cell 2013 23, 23-34DOI: (10.1016/j.ccr.2012.11.017) Copyright © 2013 Elsevier Inc. Terms and Conditions